Home » Stocks » Xenetic Biosciences

Xenetic Biosciences, Inc. (XBIO)

Stock Price: $0.870 USD -0.031 (-3.45%)
Updated Oct 21, 2020 4:00 PM EDT - Market closed
After-hours: $0.880 +0.010 (1.14%) Oct 21, 5:28 PM

Stock Price Chart

Key Info

Market Cap 5.48M
Revenue (ttm) 186,742
Net Income (ttm) -12.20M
Shares Out 6.30M
EPS (ttm) -2.45
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 21, 2020
Last Price $0.870
Previous Close $0.901
Change ($) -0.031
Change (%) -3.45%
Day's Open 0.890
Day's Range 0.860 - 0.910
Day's Volume 90,548
52-Week Range 0.440 - 1.850

More Stats

Market Cap 5.48M
Enterprise Value n/a
Earnings Date (est) Nov 12, 2020
Ex-Dividend Date n/a
Shares Outstanding 6.30M
Float 5.34M
EPS (basic) -0.27
EPS (diluted) -2.45
FCF / Share -1.02
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 452,653
Short Ratio 2.15
Short % of Float 8.48%
Beta 2.41
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 29.34
PB Ratio 0.38
Revenue 186,742
Operating Income -12.39M
Net Income -12.20M
Free Cash Flow -6.40M
Net Cash 8.07M
Net Cash / Share 1.28
Gross Margin 9.14%
Operating Margin -6,637.29%
Profit Margin -7,287.30%
FCF Margin -3,424.73%
ROA -28.86%
ROE -94.79%
ROIC -2,589.60%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (2)

Buy 2
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$2.25*
(158.59% upside)
Low
2.00
Current: $0.870
High
2.50
Target: 2.25
*Average 12-month price target from 2 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year20192018201720162015201420132012
Revenue0.02-7.593.00--1.000.29
Revenue Growth--152.83%---240.6%-
Gross Profit0.02-7.433.00--1.000.25
Operating Income-12.89-7.28-3.57-47.43-9.82-12.92-8.55-6.34
Net Income-12.78-7.30-3.60-54.21-12.51-14.31-8.58-6.33
Shares Outstanding2.850.760.720.620.350.340.300.30
Earnings Per Share-6.33-9.66-4.92-94.08-35.52-43.57-27.72-19.80
Operating Cash Flow-6.40-6.461.49-8.79-5.30-12.68-6.05-6.26
Capital Expenditures-0.02-0.01-0.020.01-0.05-0.08-0.09
Free Cash Flow-6.40-6.441.48-8.80-5.29-12.74-6.13-6.35
Cash & Equivalents10.370.645.604.110.202.574.9111.14
Total Debt----4.050.400.680.68
Net Cash / Debt10.370.645.604.11-3.852.184.2210.45
Assets21.5514.4319.1620.9716.9116.3219.4725.37
Liabilities4.334.524.864.8010.305.846.854.59
Book Value17.219.9114.3016.176.6110.4812.6220.78
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Xenetic Biosciences, Inc.
Country United States
Employees 4
CEO Jeffrey F. Eisenberg

Stock Information

Ticker Symbol XBIO
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: XBIO

Description

Xenetic Biosciences, a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and novel oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. The company is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.